Intensive glucose control offers no benefit after kidney transplant

11/5/2012 | Modern Medicine

Researchers found statistically similar rates of delayed graft function following kidney transplant in diabetes patients receiving intensive glucose control and a control group. The study in the Journal of Clinical Endocrinology & Metabolism also found an blood glucose target of less than 180 mg/dL was associated with a lower risk of organ rejection than targets of 70-110 mg/dL, suggesting tight glycemic control may offer no help immediately after the procedure.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY